Convalescent plasma for pediatric patients with COVID-19 associated acute respiratory distress syndrome

Caroline Diorio; Elizabeth Anderson; Kevin  McNerney; Eileen Goodwin; Julie Chase; Marcus Bolton; Claudia Arevalo; Madison Weirick; Sigrid Gouma; Laura Vella; Sarah Henrickson; Kathleen Chiotos; Julie Fitzgerald; Todd Kilbaugh; Audrey Odom John; Allison Blatz; Michele Lambert; Kathleen Sullivan; Margaret Tartaglione; Danielle Zambrano; Meghan Martin; Jessica Lee; Pampee Young; David Friedman; Deborah Sesok-Pizzini; Scott Hensley; Edward Behrens; Hamid Bassiri; David Teachey

doi:10.22541/au.159493393.30759606

loading page

Convalescent plasma for pediatric patients with COVID-19 associated acute respiratory distress syndrome

Caroline Diorio,
Elizabeth Anderson,
Kevin McNerney,
Eileen Goodwin,
Julie Chase,
Marcus Bolton,
Claudia Arevalo,
Madison Weirick,
Sigrid Gouma,
Laura Vella,
Sarah Henrickson,
Kathleen Chiotos,
Julie Fitzgerald,
Todd Kilbaugh,
Audrey Odom John,
Allison Blatz,
Michele Lambert,
Kathleen Sullivan,
Margaret Tartaglione,
Danielle Zambrano,
Meghan Martin,
Jessica Lee,
Pampee Young,
David Friedman,
Deborah Sesok-Pizzini,
Scott Hensley,
Edward Behrens,
Hamid Bassiri,
David Teachey

Abstract

There are no proven safe and effective therapies for children who develop life-threatening complications of SARS-CoV-2. Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2 but has theoretical risks. We report on the first use of CP in children with life-threatening COVID-19, providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.

15 Jul 2020Submission Checks Completed

Show details

Hide details

15 Jul 2020Assigned to Editor

15 Jul 2020Submitted to Pediatric Blood & Cancer

16 Jul 2020Reviewer(s) Assigned

11 Aug 2020Review(s) Completed, Editorial Evaluation Pending

13 Aug 2020Editorial Decision: Revise Minor

23 Aug 2020Submission Checks Completed

23 Aug 2020Assigned to Editor

23 Aug 20201st Revision Received

24 Aug 2020Review(s) Completed, Editorial Evaluation Pending

24 Aug 2020Editorial Decision: Accept

Abstract

Peer review status:ACCEPTED